Gilead Sciences Inc.'s push to diversify away from HIV and into cardiovascular disease kicked into high gear with the proposed $1.4 billion acquisition of CV Therapeutics Inc. and positive data from a Phase III trial of Gilead's own resistant hypertension drug, darusentan.

Gilead Sciences Inc.'s recent move to diversify away from HIV and into cardiovascular disease by acquiring CV Therapeutics Inc. may get more investor support now that Gilead's internal cardiovascular pipeline appears to be panning out. (BioWorld Today)

Genzyme Corp. bolstered its oncology portfolio through a potential $2.9 billion deal with partner Bayer AG that gives Genzyme rights to the marketed cancer drugs Campath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim) - as well as control of the Phase III alemtuzumab program in multiple sclerosis. (BioWorld Today)

Arena Pharmaceuticals Inc.'s first Phase III trial of obesity drug lorcaserin met all three of its co-primary endpoints, yet the company's shares fell 28 percent on Monday as investors questioned whether the data will be strong enough to secure a partnership and relieve Arena's cash concerns. (BioWorld Today)